Document Page: First | Prev | Next | All | Image | This Release | Search

File: 081996_jul96_decls49_0001.txt
Page: 0001
Total Pages: 3

Subject: NERVE AGENT PYRIDOSTIGMINE PRETREATMENT                         

Box  ID: BX000420

Document Number:        135

Folder Title: NBC MISCELLANEOUS INFORMATION                                                                   

Folder Seq #:          1

Unit: ARCENT      

Parent Organzation: CENTCOM     


    ROUTINE                     U N C L A s a r F  r El            TOD  OeO 1834

    RPAUZYUW RHIPAAA3414 0221533-UUUU--RUDCHAA.
    ZNR UUUUU
    R 201322Z JAN 91
    FM USCINCCENT//CCSG//
    TO RUDCHAR/CDMUSARCENT MAIN//SS/e3//
    RHIIMAA/COMUSMARCENT//SG/G3//                         rt:pvry
    RHIUFAR/USCENTAF FWD HOS ELEMENT//SG/DO//
    RUDDHAA/COMUSNAVLOSSUPFOR//Ng//                       xo
    RUHSORA/COMUSNAVCENT//SG/N3//
    RHIHDRA/SOCCENT DEPLOYED//SOCJ3//
    RHIIMDD/CG I MEF RF-AR//SS//
    INFO RUCJACC/USCENTCOM REAR MACDILL AFB FL//CC13-X// cPs
    BT                                                    PI.AHS
    UNCLAS
    MINIMIZE CONSIDERED                                    I:;IUGRAKS
    OPER/DESERT STORM//                                  lj;okce Mc
    MSBID/SYS.RRM/USCENTCOM CCSG//
    AMPN/SUBJECTo NERVE AGENT PYRIDOSTIGMINE PRETREATM
    RMKS/1. PRIMARY PROTECTION AGAINST CHEMICAL WEAPONS   IS AFF
    PROPER WEAR OF THE CHEMICAL PROTECTIVE MASK AND CHEMICAL PR
    OVERGARMENT (CPDS).
    2. NERVE AGENT PYRIDOSTISMINE PRETREATMENT (NAPP) IS TO BE
    INITIATED7 UPON DIRECTION OF UNIT COMMANDERS7 BASED ON THE     R
    OF CHEMICAL AGENT EXPOSURE. NAPP BY ITSELF DOES NOT PROVII A
    PROTECTION AGAINST NERVE AGENT. TAKEN AS DIRECTED PRIOR TO NERVE
    AGENT EXPOSURE, RESULTS OF RESEARCH STUDIES IN ANIMALS INDICATE
    THAT PYRIDOSTISMINE GREATLY ENHANCES THE EFFICACY OF THE MARK I
    NERVE AGENT ANTIDOTE KIT AND CONVULSANT ANTIDOTE NERVE AGENT CCANA).



    PAGE 02 RHIPAAA3414 UNCLAS
    3. MANY YEARS OF USE IN HUMANS FOR NON-MILITARY PURPOSES INDICATES
    THAT PYRIDOSTISMINE IS SAFE AND FREE FROM DEBILITATING SIDE EFFECTS
    IF USED AS RECOMMENDED. IT IS NOT AN "EXPERIMENTAL" DRUG. DOSAGE
    IS ONE (1) 30 MO TABLET EVERY EIGHT (-6) HOURS. IF A DOSE IS MISSED,
    DO NOT - REPEAT DO NOT9 TAKE TWO TABLETS AT ONCE - MERELY START
    AGAIN WITH ONE TABLET EVERY EIGHT HOURS. TAKING MORE THAN ONE TABLET
    AT A TIME DOES NOT PROVIDE ANY ADDITIONAL PROTECTION AND MAY BE
    HAZARDOUS.
   4. THE CHEMICAL THREAT, AND NEED TO CONTINUE NAPP, SHOULD BE
    REEVALUATED EVERY THREE DAYS AT A MINIMUM. THERE ARE NO
    CONTRAINDICATIONS TO REPEATED STARTS AND STOPS OF NAPP
    ADMINISTRATION, BUT DECISION TO DO SO SHOULD BE BASED ON THREAT
    ASSESSMENT AND TACTICAL SITUATION. ADMINISTRATION BEYOND 21 DAYS
    IS NOT RECOMMENDED WITHOUT A THOROUGH EVALUATION OF THE SITUATION.
    5. POC AT USCENTCOM CCSS IS LTC WADE, TAC 9-8963-7699 COMMERCIAL
    011-966-1-478-4466 EXT 110.//
    BT
    #3414


    ROUTINE                      U N C L A S S I F I E D

Document Page: First | Prev | Next | All | Image | This Release | Search


Document 3 f:/Week-29/BX000420/NBC MISCELLANEOUS INFORMATION/nerve agent pyridostigmine pretreatment:08169613350856
Control Fields 17
File Room = jul96_declassified
File Cabinet = Week-29
Box ID = BX000420
Unit = ARCENT
Parent Organization = CENTCOM
Folder Title = NBC MISCELLANEOUS INFORMATION
Folder Seq # = 1
Subject = NERVE AGENT PYRIDOSTIGMINE PRETREATMENT
Document Seq # = 56
Document Date =
Scan Date = 30-JUL-1996
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 16-AUG-1996